Get the Stockscreener App
22.47
1.75%
-0.40
After Hours:
22.47
Enliven Therapeutics Inc stock is traded at $22.47, with a volume of 376.12K.
It is down -1.75% in the last 24 hours and down -11.64% over the past month.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
See More
Previous Close:
$22.87
Open:
$22.51
24h Volume:
376.12K
Relative Volume:
1.43
Market Cap:
$1.10B
Revenue:
-
Net Income/Loss:
$-82.83M
P/E Ratio:
-18.10
EPS:
-1.2413
Net Cash Flow:
$-72.22M
1W Performance:
-2.94%
1M Performance:
-11.64%
6M Performance:
+6.80%
1Y Performance:
+84.33%
1-Day Range:
$21.83
$22.99
1-Week Range:
$21.83
$24.42
52-Week Range:
$10.90
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
22.47 | 1.10B | 0 | -82.83M | -72.22M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
Enliven Therapeutics Inc Stock (ELVN) Latest News
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Wellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
When the Price of (ELVN) Talks, People Listen - Stock Traders Daily
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Clear Street sets Enliven Therapeutics stock to buy with $36 target - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat
Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat
Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock - Investing.com
Comparing Enliven Therapeutics (NASDAQ:ELVN) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3%What's Next? - MarketBeat
Ally Bridge Group NY LLC Takes $6 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com
(ELVN) Investment Analysis - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com
Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat
Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Enliven Therapeutics has cash runway into late 2026 - BizWest
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat
RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com
COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com
Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com
Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks
Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
How to Take Advantage of moves in (ELVN) - Stock Traders Daily
Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com
Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN
Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India
Enliven Therapeutics CFO sells $24,422 in stock - Investing.com
Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com
Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):